VFA
SCPH

Valeo Financial Advisors’s scPharmaceuticals SCPH Stock Holding History

Valeo Financial Advisors’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-20
Closed – – 1702
2019
Q3 		$0 Hold
20
– – ﹤0.01% 1656
2019
Q2 		$0 Hold
20
– – ﹤0.01% 1647
2019
Q1 		$0 Buy
+20
New +$69 ﹤0.01% 1624

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
AIM
Alambic Investment Management Belvedere, California $9.12M AUM 34.55% 1-Year Est. Return

Valeo Financial Advisors's SCPH Position: Q4 2019 in Review

Valeo Financial Advisors sold out of scPharmaceuticals (SCPH) in Q4 2019, closing a stake of 20 shares.

Valeo Financial Advisors first reported a position in SCPH in Q1 2019 and held it in 3 quarters. The position peaked at $0 in Q3 2019. 27 funds tracked by Wall St. Rank hold SCPH as of Q4 2019.

  • Valeo Financial Advisors reported no remaining scPharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Valeo Financial Advisors sold 20 scPharmaceuticals shares in Q4 2019.
  • Valeo Financial Advisors first reported a position in scPharmaceuticals in Q1 2019 and held it in 3 quarters.
  • Valeo Financial Advisors's scPharmaceuticals position peaked at $0 in Q3 2019.
  • 27 funds tracked by Wall St. Rank held scPharmaceuticals as of Q4 2019.

Based on Valeo Financial Advisors's 13F filing for Q4 2019, filed 24 Jan 2020.